NASDAQ
14.36USD
+0.12 (+0.84%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
210.8M
P/E
—
EPS
—
Beta
1.45
52W range
7.78-34.1
Day range
14.20–14.74
Open
14.52
Prev close
14.24
Volume
88.5K
Avg volume
156.9K
Dividend
0.00
IPO
2020-09-25
https://seekingalpha.com/article/4922499-greenwich-lifesciences-stock-overlooked-need · 7/16/2026+1.00
https://www.defenseworld.net/2026/01/18/head-to-head-contrast-greenwich-lifesciences-nasdaqglsi-vertex-pharmaceuticals-nasdaqvrtx.html · 1/18/2026+0.00
https://www.globenewswire.com/news-release/2025/12/22/3209047/0/en/Greenwich-LifeSciences-Provides-Additional-Updates-on-FLAMINGO-01-and-Corporate-Strategy.html · 12/22/2025+0.80
https://www.globenewswire.com/news-release/2025/09/18/3152237/0/en/Greenwich-LifeSciences-Announces-Expansion-of-Flamingo-01-Clinical-Trial-to-Ireland.html · 9/18/2025+0.60
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
